NasdaqCM:CPRXBiotechs
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Reports Strong Q1 2025 Earnings Growth
Catalyst Pharmaceuticals (NasdaqCM:CPRX) recently appointed Dr. William T. Andrews as Chief Medical Officer, a move that underscores the company's focus on advancing its leadership in rare disease therapeutics. Over the last quarter, Catalyst Pharmaceuticals' stock experienced a price move of 2.74%. This moderate gain aligns with broader market trends that saw a 9.8% increase over the year, alongside earnings growth anticipation. Moreover, the company's strong earnings report, with Q1 2025...